Clinical Trials Logo

Relapsed Follicular Lymphoma clinical trials

View clinical trials related to Relapsed Follicular Lymphoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04191187 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

Start date: December 6, 2019
Phase: Phase 2
Study type: Interventional

This is a single arm, phase II trial of HLA-haploidentical related hematopoietic cells transplant (Haplo-HCT) using reduced intensity conditioning (fludarabine and melphalan and total body irradiation). Peripheral blood is the donor graft source. This study is designed to estimate disease-free survival (DFS) at 18 months post-transplant.

NCT ID: NCT02956382 Active, not recruiting - Clinical trials for Refractory Follicular Lymphoma

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Start date: March 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.

NCT ID: NCT01827605 Active, not recruiting - Clinical trials for Relapsed Follicular Lymphoma

A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

Start date: January 2012
Phase: Phase 3
Study type: Interventional

This is a Phase III, multicenter, open-label, randomized and controlled study to compare the efficacy of a consolidation therapy with RIT versus ASCT in patients with FL in CR or PR after second or third line chemotherapy supplemented with rituximab.